Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8014009rdf:typepubmed:Citationlld:pubmed
pubmed-article:8014009lifeskim:mentionsumls-concept:C0000742lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C0024299lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C0032131lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C1521991lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C0439831lld:lifeskim
pubmed-article:8014009lifeskim:mentionsumls-concept:C1514873lld:lifeskim
pubmed-article:8014009pubmed:issue1lld:pubmed
pubmed-article:8014009pubmed:dateCreated1994-7-26lld:pubmed
pubmed-article:8014009pubmed:abstractTextMutants and fusion products of the c-abl gene were used to define some of the molecular requirements for rapid plasmacytoma (PC) and pre-B-lymphoma induction in pristane-treated N-myc transgenic BALB/c mice. A-MuLV induced PCs in 21 of 25 mice with a mean post-pristane latency period of 46 +/- 9 days, compared to 134 +/- 25 days in controls exposed to pristane alone. delta XB, a mutant of type IV c-abl with a deletion of the SH3 domain, was equally effective in inducing PCs in 7 of 7 mice with a latency period of 49 +/- 7 days, indicating that gag sequences are not required for rapid PC induction. The delta XB delta Nar mutant that carried a large C-terminal deletion in addition showed only a negligible activity, if any, suggesting that PC acceleration requires the C-terminal domain in the same way as lymphoid transformation and in contrast to fibroblast transformation. BCR-ABL fusion constructs encoding an 185-kDa protein as in acute leukemia, or a 210-kDa protein as in chronic myelocytic leukemia (CML), did not accelerate pristane-induced PC development in the N-myc transgenic mice, in contrast to their known ability to immortalize lymphoid cells in vitro. Only one of 14 non-transgenic littermates developed a pre-B lymphoma after A-MuLV infection, and none of 10 normal littermates infected with delta XB virus developed a construct-carrying tumor. This result suggests that PC acceleration is due to co-operative interaction of the N-myc transgene and activated abl. Infection of N-myc transgenic bone marrow or spleen cells with A-MuLV in vitro led to the outgrowth of pre-B lymphomas after transplantation to pristane-treated BALB/c recipients. The lymphoma-inducing activity of A-MuLV depends on its high titer, since diluted A-MuLV or the lower-titered delta XB induced only PCs under the same conditions. The v-abl, delta XB and BCR-ABL-carrying viruses generated immortalized lymphoblastoid lines in vitro, regardless of the presence of the N-myc transgene, suggesting that lymphoid transformation is a direct function of appropriate abl sequences in contrast to PC acceleration.lld:pubmed
pubmed-article:8014009pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8014009pubmed:languageenglld:pubmed
pubmed-article:8014009pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8014009pubmed:citationSubsetIMlld:pubmed
pubmed-article:8014009pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8014009pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8014009pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8014009pubmed:statusMEDLINElld:pubmed
pubmed-article:8014009pubmed:monthJullld:pubmed
pubmed-article:8014009pubmed:issn0020-7136lld:pubmed
pubmed-article:8014009pubmed:authorpubmed-author:KleinGGlld:pubmed
pubmed-article:8014009pubmed:authorpubmed-author:JacksonPPlld:pubmed
pubmed-article:8014009pubmed:authorpubmed-author:WangYYlld:pubmed
pubmed-article:8014009pubmed:authorpubmed-author:SugiyamaHHlld:pubmed
pubmed-article:8014009pubmed:authorpubmed-author:SawyersC LCLlld:pubmed
pubmed-article:8014009pubmed:issnTypePrintlld:pubmed
pubmed-article:8014009pubmed:day1lld:pubmed
pubmed-article:8014009pubmed:volume58lld:pubmed
pubmed-article:8014009pubmed:geneSymbolgaglld:pubmed
pubmed-article:8014009pubmed:geneSymbolmyclld:pubmed
pubmed-article:8014009pubmed:geneSymbolc-abllld:pubmed
pubmed-article:8014009pubmed:geneSymbolN-myclld:pubmed
pubmed-article:8014009pubmed:geneSymbolv-abllld:pubmed
pubmed-article:8014009pubmed:ownerNLMlld:pubmed
pubmed-article:8014009pubmed:authorsCompleteYlld:pubmed
pubmed-article:8014009pubmed:pagination135-41lld:pubmed
pubmed-article:8014009pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:meshHeadingpubmed-meshheading:8014009-...lld:pubmed
pubmed-article:8014009pubmed:year1994lld:pubmed
pubmed-article:8014009pubmed:articleTitleMolecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.lld:pubmed
pubmed-article:8014009pubmed:affiliationMicrobiology and Tumorbiology Center (MTC), Karolinska Institute, Stockholm, Sweden.lld:pubmed
pubmed-article:8014009pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8014009pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:8014009pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8014009pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed